Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has issued an update.
Zylox-Tonbridge Medical Technology Co., Ltd. has announced a final ordinary cash dividend of RMB 0.22 per share for the financial year ended 31 December 2025, approved by shareholders on 13 May 2026. For H share investors in Hong Kong, the dividend will be paid in Hong Kong dollars at HKD 0.2515764 per share, based on an exchange rate of RMB 1 to HKD 1.143529, with an ex-dividend date of 27 May 2026 and payment scheduled for 18 June 2026.
The company has also detailed withholding tax arrangements, applying a 10% enterprise income tax for overseas non-resident enterprise shareholders of H shares and a 20% individual income tax for domestic individual shareholders under the H share full circulation scheme. These updates clarify the net dividend entitlements for different shareholder groups and provide greater transparency on the tax treatment and timetable surrounding the 2025 final dividend distribution.
The most recent analyst rating on (HK:2190) stock is a Buy with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a Hong Kong-listed medical technology company, with its H shares traded under stock code 02190. The company operates in the healthcare sector, focusing on the development and commercialization of medical technologies and devices for patients in mainland China and international markets.
Average Trading Volume: 741,252
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.65B
See more insights into 2190 stock on TipRanks’ Stock Analysis page.